Id	Study	Session	StudySession	SL	TL	Task	Text	Part	SGroup	TGroup	STid	SGid	STseg	TokS	LenS	TTid	TGid	TTseg	TokT	LenT	Ins	Del	Munit	InEff	FixS	TrtS	OrtS	OrtT	MU1rtS	MU1rtT	FFTimeS	FFDurS	FixT	TrtT	FFTimeT	FFDurT	CrossS	CrossT	Pause	Dur	End	Edit	Pause1	Time1	Ins1	Del1	Dur1	End1	Edit1	Pause2	Time2	Ins2	Del2	Dur2	End2	Edit2	PauseR	TimeR	InsR	DelR	DurR	EditR	Edit
1	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	How	Wie	1	1	1	1	3	1	1	1	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
2	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	does_work	wirkt	2	2+4	1	2	8	2	2	1	1	9	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1732	64569	82525	[wirkt_	1732	17956	6	0	733	18689	wirkt_[	0	0	0	0	0	0	---	0	0	0	0	0	---	[wirkt_
3	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	3	3	1	1	8	3	3	1	1	8	0	4	2	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	-1	13899	4057	17956	[zu__	13182	13182	0	1	0	13182	zu_	717	16224	0	1	0	16224	_]	0	0	0	0	0	---	[zu__
4	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	?	?	5	5	1	1	1	4	4	1	1	1	0	2	1	-3.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2325	717	16224	arbeiten	2325	15507	0	1	0	15507	arbeiten	0	0	0	0	0	0	---	0	0	0	0	0	---	arbeiten
5	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	The	Der	6	6	2	1	3	5	5	2	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
6	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	active_substance	Wirkstoff	7	7+8	2	2	15	6	6	2	1	16	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	2	63836	296	82821	[ni	63836	82525	0	2	124	82649	ni]	0	0	0	0	0	0	---	0	0	0	0	0	---	[ni
7	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	in	von	9	9	2	1	2	7	7	2	1	2	6	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	172	7705	90526	[von	172	82821	3	0	203	83024	von[	0	0	0	0	0	0	---	0	0	0	0	0	---	[von
8	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	10	10	2	1	8	8	8	2	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
9	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,	,	11	11	2	1	1	9	9	2	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
10	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	topotecan	Topotecan	12	12	2	1	9	10	10	2	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
11	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,	,	13	13	2	1	1	11	11	2	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
12	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	is	ist	14	14	2	1	2	12	12	2	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
13	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	an	ein	15	15	2	1	2	13	13	2	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
14	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	anticancer	gegen_Krebs	16	16	2	1	10	15	15+16	2	2	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
15	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	medicine	Arzneimittel	17	17	2	1	8	14	14	2	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
16	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	that	,_das	18	18	2	1	4	17	17+18	2	2	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	4	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
17	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	belongs	gehört	19	19	2	1	7	27	27	2	1	7	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	9	1	1560	827	96955	[gehört	1560	96128	6	0	717	96845	gehört	0	0	0	0	0	0	---	0	0	0	0	0	---	[gehört
18	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	to_the	zur	20	20+21	2	2	5	19	19	2	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-8	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
19	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	group	Gruppe	22	22	2	1	5	20	20	2	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
20	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	""""	""""	23	23	2	1	1	22	22	2	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
21	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	topoisomerase_inhibitors	der_Topoisomerase_-_Hemmer	24	24+25	2	2	23	21	21+23+24+25	2	4	21	6	4	1	3.6667	0	0	0	0	0	0	0	0	0	0	0	0	3	2	7502	5602	96128	[gehört]der[.	7502	90526	3	2	4042	94568	gehört]der[.]	0	0	0	0	0	0	---	0	0	0	0	0	---	[gehört]der[.
22	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	26	26	2	1	1	28	28	2	1	1	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	110	20685	117640	.	110	96955	1	0	0	96955	.[	0	0	0	0	0	0	---	0	0	0	0	0	---	.
23	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	It	Es	28	28	3	1	2	29	29	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
24	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	blocks	blockiert	29	29	3	1	6	30	30	3	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
25	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	an	das	30	30	3	1	2	31	31	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
26	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	enzyme	Enzym	31	31	3	1	6	32	32	3	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
27	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	topoisomerase	Topoisomerase	33	33	3	1	13	33	33	3	1	13	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
28	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	I	I	34	34	3	1	1	34	34	3	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
29	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,	,	35	35	3	1	1	35	35	3	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
30	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	which	das	36	36	3	1	5	36	36	3	1	5	18	22	2	-13.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	1	51979	76207	506988	[ei]as[ni]an[na]im[mi]beiieb	20685	117640	9	8	32230	149870	ei]as[ni]an[na]im[mi]bei[	0	0	0	0	0	0	---	31294	506504	0	3	328	ieb]	[ei]as[ni]an[na]im[mi]beiieb
31	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	is	ist	37	37	3	1	2	43	43	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	7	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
32	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	involved	beteiligt	38	38	3	1	8	42	42	3	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
33	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	in	an	39	39	3	1	2	37	37	3	1	2	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-5	1	156	26317	533305	[an	0	0	0	0	0	0	---	0	0	0	0	0	0	---	156	506988	2	0	483	an[	[an
34	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	der	40	40	3	1	3	38	38	3	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
35	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	division	Teilung	41	41	3	1	8	39	39	3	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
36	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	of	der	42	42	3	1	2	40	40	3	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
37	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	DNA	DNA	43	43	3	1	3	41	41	3	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
38	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	44	44	3	1	1	44	44	3	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
39	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	an	---	27	89	3	1	2	0	0	0	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	45	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
40	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	an	---	32	89	3	1	2	0	0	0	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
41	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	When	Wenn	45	45	4	1	4	45	45	4	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	-44	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
42	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	das	46	46	4	1	3	46	46	4	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
43	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	enzyme	Enzym	47	47	4	1	6	47	47	4	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
44	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	is	ist	48	48	4	1	2	49	49	4	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
45	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	blocked	blockiert	49	49	4	1	7	48	48	4	1	7	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
46	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,	,	50	50	4	1	1	50	50	4	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
47	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	die	51	51	4	1	3	52	52	4	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
48	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	DNA	DNA_-	52	52	4	1	3	53	53+54	4	2	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
49	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	strands	Stränge	53	53	4	1	7	55	55	4	1	7	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
50	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	break	brechen	54	54	4	1	5	51	51	4	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-4	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
51	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	55	55	4	1	1	56	56	4	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
52	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	This	Dies	56	56	5	1	4	57	57	5	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
53	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	prevents	verhindert	57	57	5	1	8	58	58	5	1	8	10	14	2	-8.3333	0	0	0	0	0	0	0	0	0	0	0	0	1	1	50762	2232	218823	[dass_die_,]_eine[enie	43493	193363	5	3	1014	194377	dass_die_,]_eine	7269	217746	0	4	921	218667	enie]	0	0	0	0	0	---	[dass_die_,]_eine[enie
54	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	der	58	58	5	1	3	61	61	5	1	3	6	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	93	4602	200430	der	93	195828	3	0	234	196062	der[	0	0	0	0	0	0	---	0	0	0	0	0	---	der
55	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	cancer_cells	Krebszellen	59	59+60	5	2	11	62	62	5	1	12	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	2	4368	733	201163	[an_der_Teilung,_und_sie_schließlich_sterben_	4368	200430	0	2	187	200617	an_der_Teilung,_und_sie_schließlich_sterben_]	0	0	0	0	0	0	---	0	0	0	0	0	---	[an_der_Teilung,_und_sie_schließlich_sterben_
56	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	from	die	61	61	5	1	4	59	59	5	1	4	8	0	2	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-3	1	297	12604	231178	_[die	141	194518	1	0	0	194518	_	156	218823	3	0	920	219743	die	0	0	0	0	0	---	_[die
57	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	dividing	Teilung	62	62	5	1	8	60	60	5	1	8	16	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	249	1061	195828	Teilung_	249	194767	8	0	968	195735	Teilung_	0	0	0	0	0	0	---	0	0	0	0	0	---	Teilung_
58	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	and	,_was	63	63	5	1	3	63	63+64	5	2	2	14	2	1	1.3077	0	0	0	0	0	0	0	0	0	0	0	0	4	1	546	1170	202333	[,_y[y]was_	546	201163	7	1	1046	202209	,_y[y]was_	0	0	0	0	0	0	---	0	0	0	0	0	---	[,_y[y]was_
59	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	they_die	zu_deren_Tod_führt	64	64+66	5	2	7	66	66+67+68+69	5	4	5	42	6	1	1.3243	0	0	0	0	0	0	0	0	0	0	0	0	5	3	312	13182	217746	zu_deren_Abs[sbA]Tod_führt	312	204564	21	3	5913	210477	zu_deren_Abs[sbA]Tod_führt[	0	0	0	0	0	0	---	0	0	0	0	0	---	zu_deren_Abs[sbA]Tod_führt
60	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	eventually	schließlich	65	65	5	1	10	65	65	5	1	10	24	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-4	-1	124	2231	204564	schließlich_	124	202333	12	0	1919	204252	schließlich_	0	0	0	0	0	0	---	0	0	0	0	0	---	schließlich_
61	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	67	67	5	1	1	70	70	5	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
62	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	68	68	6	1	8	71	71	6	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
63	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	also	auch	69	69	6	1	4	74	74	6	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
64	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	affects	wirkt_sich_auf_aus	70	70	6	1	7	72	72+73+75+79	6	4	4	8	2	1	1.5714	0	0	0	0	0	0	0	0	0	0	0	0	5	1	140	20608	251926	auf[f]s	140	231318	4	1	1654	232972	auf[f]s	0	0	0	0	0	0	---	0	0	0	0	0	---	auf[f]s
65	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	non	Nicht	71	71	6	1	3	76	76	6	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
66	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	-	-	72	72	6	1	1	77	77	6	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
67	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	cancer_cells	Krebszellen	73	73+74	6	2	11	78	78	6	1	12	2	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	11435	140	231318	_	11435	231178	1	0	0	231178	_	0	0	0	0	0	0	---	0	0	0	0	0	---	_
68	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,	,	75	75	6	1	1	80	80	6	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
69	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	which	was	76	76	6	1	5	81	81	6	1	5	12	12	1	25.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	18954	20015	271941	was_zu[eid_uz	18954	251926	6	6	10686	262612	was_zu[eid_uz	0	0	0	0	0	0	---	0	0	0	0	0	---	was_zu[eid_uz
70	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	causes	verursacht	77	77	6	1	6	83	83	6	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
71	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	side_effects	Nebenwirkungen	78	78+79	6	2	11	82	82	6	1	12	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
72	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	80	80	6	1	1	84	84	6	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
73	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	How	Wie	81	81	7	1	3	85	85	7	1	3	0	6	1	-1.4000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	9329	437	272378	tah	9329	271941	0	3	281	272222	tah]	0	0	0	0	0	0	---	0	0	0	0	0	---	tah
74	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	has_been	wurde	82	82+84	7	2	7	86	86	7	1	8	10	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	156	16754	289132	[wurde	156	272378	5	0	530	272908	wurde[	0	0	0	0	0	0	---	0	0	0	0	0	---	[wurde
75	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	83	83	7	1	8	87	87	7	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	-1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
76	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	studied	untersucht	85	85	7	1	7	88	88	7	1	7	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
77	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	?	?	86	86	7	1	1	89	89	7	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
78	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	87	87	8	1	8	90	90	8	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
79	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	as	als	88	88	8	1	2	91	91	8	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
80	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	infusion	Infusion	90	90	8	1	8	92	92	8	1	8	0	6	1	-1.4000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	16224	734	289866	[tah	16224	289132	0	3	500	289632	tah]	0	0	0	0	0	0	---	0	0	0	0	0	---	[tah
81	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	has_been	wurde	91	91+92	8	2	7	93	93	8	1	8	10	4	1	2.1429	0	0	0	0	0	0	0	0	0	0	0	0	1	2	234	5740	295606	[wurde[ni	234	289866	5	2	5600	295466	wurde[ni]	0	0	0	0	0	0	---	0	0	0	0	0	---	[wurde[ni
82	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	studied	untersucht	93	93	8	1	7	114	114	8	1	7	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	21	1	2262	41793	361096	[worden_	2262	319303	0	2	374	319677	worden_	0	0	0	0	0	0	---	0	0	0	0	0	---	[worden_
83	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	in	bei	94	94	8	1	2	94	94	8	1	2	6	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-20	1	140	12465	308071	[bei	140	295606	3	0	141	295747	bei	0	0	0	0	0	0	---	0	0	0	0	0	---	[bei
84	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	more	mehr	95	95	8	1	4	95	95	8	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
85	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	than	als	96	96	8	1	4	96	96	8	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
86	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	480	480	97	97	8	1	3	97	97	8	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
87	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	women	Frauen	98	98	8	1	5	98	98	8	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
88	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	with	mit	99	99	8	1	4	99	99	8	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
89	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	ovarian_cancer	Eierstockkrebs	100	100+101	8	2	13	100	100	8	1	14	0	2	1	-3.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	25834	0	533305	[_]	0	0	0	0	0	0	---	0	0	0	0	0	0	---	25834	533305	0	1	0	_]	[_]
90	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	who	,_bei_denen_,	102	102	8	1	3	101	101+102+103+113	8	4	0	18	4	2	1.5333	0	0	0	0	0	0	0	0	0	0	0	0	13	1	13993	9563	319303	bei_[ei]enen[,	12324	308071	8	2	3666	311737	bei_[ei]enen[	1669	317041	1	0	0	317041	,[	0	0	0	0	0	---	bei_[ei]enen[,
91	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	had	war	103	103	8	1	3	112	112	8	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
92	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	failed	gescheitert	104	104	8	1	6	111	111	8	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
93	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	one	eine	105	105	8	1	3	104	104	8	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-7	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
94	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	treatment	Behandlung	106	106	8	1	9	105	105	8	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
95	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	with	mit	107	107	8	1	4	106	106	8	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
96	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	platinum_-_containing	platinhaltigen	108	108+109+110	8	3	19	107	107	8	1	21	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
97	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	anticancer	gegen_Krebs	111	111	8	1	10	109	109+110	8	2	9	0	2	1	-3.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	3635	1669	317041	[,	3635	315372	0	1	0	315372	,]	0	0	0	0	0	0	---	0	0	0	0	0	---	[,
98	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	medicines	Arzneimitteln	112	112	8	1	9	108	108	8	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
99	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	113	113	8	1	1	115	115	8	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	7	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
100	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Three	Drei	114	114	9	1	5	116	116	9	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
101	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	studies	Studien	115	115	9	1	7	117	117	9	1	7	0	10	1	-1.2222	0	0	0	0	0	0	0	0	0	0	0	0	1	1	41419	2464	363560	neies	41419	361096	0	5	967	362063	neies]	0	0	0	0	0	0	---	0	0	0	0	0	---	neies
102	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	were	waren	116	116	9	1	4	118	118	9	1	4	10	2	1	1.4444	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1497	4353	367913	"[waren["""	1497	363560	5	1	3947	367507	"waren[""]"	0	0	0	0	0	0	---	0	0	0	0	0	---	"[waren["""
103	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	""""	,,	117	117	9	1	1	119	119	9	1	1	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	406	8393	376306	[,,	406	367913	2	0	156	368069	,,[	0	0	0	0	0	0	---	0	0	0	0	0	---	[,,
104	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	open	offen	118	118	9	1	4	120	120	9	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
105	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,	,	119	119	9	1	1	122	122	9	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
106	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	""""	""""	120	120	9	1	1	121	121	9	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
107	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	meaning	was_bedeutet	121	121	9	1	7	123	123+124	9	2	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
108	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	that	,_dass_dass	122	122	9	1	4	125	125+126+137	9	3	2	10	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	13	1	7161	5273	399441	dass_	7161	394168	5	0	530	394698	dass_[	0	0	0	0	0	0	---	0	0	0	0	0	---	dass_
109	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	das	123	123	9	1	3	127	127	9	1	3	6	20	1	-2.0769	0	0	0	0	0	0	0	0	0	0	0	0	-10	1	8237	2199	378505	[nizideM_ei]as_	8237	376306	3	10	1731	378037	nizideM_ei]as_	0	0	0	0	0	0	---	0	0	0	0	0	---	[nizideM_ei]as_
110	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	medicine	Medikament	124	124	9	1	8	128	128	9	1	8	20	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	468	7676	386181	Medikament	468	378505	10	0	1030	379535	Medikament	0	0	0	0	0	0	---	0	0	0	0	0	---	Medikament
111	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	was	wurde	125	125	9	1	3	135	135	9	1	3	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	7	1	6646	7987	394168	wurde_	6646	386181	6	0	826	387007	wurde_	0	0	0	0	0	0	---	0	0	0	0	0	---	wurde_
112	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	not	nicht	126	126	9	1	3	129	129	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-6	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
113	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	compared	verglichen	127	127	9	1	8	134	134	9	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	5	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
114	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	to	mit	128	128	9	1	2	130	130	9	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-4	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
115	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	any	einer	129	129	9	1	3	131	131	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
116	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	other	anderen	130	130	9	1	5	132	132	9	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
117	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	treatment	Behandlung	131	131	9	1	9	133	133	9	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
118	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	and	und	132	132	9	1	3	136	136	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
119	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	die	133	133	9	1	3	138	138	9	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
120	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	patients	Patienten	134	134	9	1	8	139	139	9	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
121	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	knew	wussten	135	135	9	1	4	140	140	9	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
122	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	that	,_dass	136	136	9	1	4	141	141+142	9	2	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
123	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	they	sie	137	137	9	1	4	143	143	9	1	4	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	1	249	2122	401812	e_	249	399690	0	2	187	399877	e_]	0	0	0	0	0	0	---	0	0	0	0	0	---	e_
124	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	were_receiving	erhielten	138	138+139	9	2	13	145	145	9	1	14	4	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	2	686	19610	422108	erhielten	686	402498	2	0	515	403013	erhielten[	0	0	0	0	0	0	---	0	0	0	0	0	---	erhielten
125	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	140	140	9	1	8	144	144	9	1	8	2	2	2	5.0000	0	0	0	0	0	0	0	0	0	0	0	0	-1	1	6678	935	402498	[rhielten[_	4743	399441	0	1	0	399441	rhielten	1935	401812	1	0	0	401812	_	0	0	0	0	0	---	[rhielten[_
126	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	141	141	9	1	1	146	146	9	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
127	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	The	Die	142	142	10	1	3	147	147	10	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
128	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	fourth	vierte	143	143	10	1	6	148	148	10	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
129	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	study	Studie	144	144	10	1	5	149	149	10	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
130	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	involved	umfasste	145	145	10	1	8	150	150	10	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
131	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	226	226	146	146	10	1	3	151	151	10	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
132	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	women	Frauen	147	147	10	1	5	152	152	10	1	5	0	2	1	-3.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	19095	3322	425430	[,	19095	422108	0	1	0	422108	,	0	0	0	0	0	0	---	0	0	0	0	0	---	[,
133	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	,_and	und	148	148+149	10	2	4	153	153	10	1	5	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
134	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	compared	verglich	150	150	10	1	8	154	154	10	1	8	0	4	1	-1.6667	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3322	30748	456178	ne	3322	425430	0	2	1248	426678	ne]	0	0	0	0	0	0	---	0	0	0	0	0	---	ne
135	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	Hycamtin	Hycamtin	151	151	10	1	8	155	155	10	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
136	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	with	mit	152	152	10	1	4	156	156	10	1	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
137	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	paclitaxel	Paclitaxel	153	153	10	1	10	157	157	10	1	10	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
138	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	(	(	154	154	10	1	1	158	158	10	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
139	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	another	ein_anderes	155	155	10	1	7	159	159+160	10	2	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
140	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	anticancer	gegen_Krebs	156	156	10	1	10	162	162+163	10	2	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
141	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	medicine	Arzneimittel	157	157	10	1	8	161	161	10	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
142	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	)	)	158	158	10	1	1	164	164	10	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
143	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	159	159	10	1	1	165	165	10	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
144	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	The	Der	160	160	11	1	3	166	166	11	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
145	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	main_measure	Hauptindikator	161	161+162	11	2	11	167	167	11	1	12	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
146	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	of	für	163	163	11	1	2	168	168	11	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
147	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	effectiveness	Wirksamkeit	164	164	11	1	13	170	170	11	1	13	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
148	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	was	war	165	165	11	1	3	171	171	11	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
149	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	the	die	166	166	11	1	3	172	172	11	1	3	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
150	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	number	Anzahl	167	167	11	1	6	173	173	11	1	6	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
151	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	of	der	168	168	11	1	2	174	174	11	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
152	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	patients	Patienten	169	169	11	1	8	175	175	11	1	8	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
153	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	whose	,_deren	170	170	11	1	5	176	176+177	11	2	4	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
154	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	tumours	Tumore	171	171	11	1	7	178	178	11	1	7	0	2	1	-3.0000	0	0	0	0	0	0	0	0	0	0	0	0	1	1	18361	31294	506504	[n	0	0	0	0	0	0	---	0	0	0	0	0	0	---	18361	475210	0	1	0	n	[n
155	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	responded	ansprach	172	172	11	1	9	182	182	11	1	9	12	0	1	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	4	1	29500	19032	475210	[sprach	29500	456178	6	0	671	456849	sprach[	0	0	0	0	0	0	---	0	0	0	0	0	---	[sprach
156	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	to	auf	173	173	11	1	2	179	179	11	1	2	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	-3	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
157	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	treatment	Behandlung	174	174	11	1	9	181	181	11	1	9	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---
158	OCT13	P02_PL03	OCT13@P02_PL03	en	de	PL	03	P02	.	.	175	175	11	1	1	183	183	11	1	1	0	0	0	1.0000	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	0	---	0	0	0	0	0	---	---